FDAnews
www.fdanews.com/articles/195055-csa-medical-receives-ce-mark-for-cryospray-copd-treatment

CSA Medical Receives CE Mark for Cryospray COPD Treatment

December 8, 2019

CSA Medical has earned the CE Mark for its RejuvenAir system, a liquid nitrogen delivery device that is designed for treating chronic obstructive pulmonary disease (COPD) patients with chronic bronchitis.

The system delivers spray-liquid nitrogen at -320.8F to a patient’s central airways through a minimally invasive bronchoscopic procedure, freezing damaged lung cells so they can heal.

The company’s yearlong trial of the device, which treated 35 patients using its metered cryospray, demonstrated quality of life scores that were superior to the pharmacologic standard of care.

View today's stories